title: How we manage prostate biopsy and prostate cancer therapy in men with haemophilia.
abstract: A 56-year-old African American male with severe haemophilia A [baseline factor VIII (FVIII) activity <1%] and chronic hepatitis C virus infection started annual serial monitoring of prostate-specific antigen (PSA) at age 40 because of a family history of prostate cancer (his father died from the disease at age 63). His most recent PSA level was 4.4 ng L (-1); previous values were <3 ng L(-1 . Digital rectal examination was unrevealing.
authors.affiliation: Penn Comprehensive Hemophilia and Thrombosis Program, University of Pennsylvania, Philadelphia, PA 19104, USA. patrick.fogarty@uphs.upenn.edu
authors.forename: P F
authors.initials: PF
authors.lastname: Fogarty
authors.forename: P
authors.initials: P
authors.lastname: Kouides
mesh_terms: D001706:Biopsy / Q000379:methods*; D003029:Coagulants / Q000008:administration & dosage*; D005169:Factor VIII / Q000008:administration & dosage*; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery
chemical_list: D003029:Coagulants; D005169:Factor VIII; D017430:Prostate-Specific Antigen